Ken Griffin Passage Bio, Inc. Put Options Transaction History
Citadel Advisors LLC
- $483 Billion
- Q2 2024
Put Options
4 transactions
Others Institutions Holding PASG
# of Institutions
45Shares Held
32.7MCall Options Held
8.3KPut Options Held
400-
Orbimed Advisors LLC San Diego, CA10.1MShares$6.07 Million0.19% of portfolio
-
Vestal Point Capital, LP New York, NY6.05MShares$3.63 Million0.36% of portfolio
-
Versant Venture Management, LLC San Francisco, CA4.03MShares$2.42 Million7.06% of portfolio
-
New Leaf Venture Partners, L.L.C. New York, NY2.5MShares$1.5 Million2.4% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.07MShares$1.24 Million0.0% of portfolio
About Passage BIO, Inc.
- Ticker PASG
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 54,463,200
- Market Cap $32.7M
- Description
- Passage Bio, Inc., a genetic medicines company, develops transformative therapies for central nervous system diseases. It develops PBGM01, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GLB1 gene encoding lysosomal acid beta-galactosidase for infantile GM1; PBFT02, which utilizes an AAV1 ...